RxSight, Inc. RXST
Nasdaq · XNAS · stock · Ophthalmic Goods
Chart by TradingView
2/9
Piotroski F — financial health
5.56
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $134.5M | -$38.9M | $103.0M | -$19.3M | $275.7M |
| 2024 | $139.9M | -$27.5M | $98.9M | -$22.4M | $281.2M |
| 2023 | $89.1M | -$48.6M | $53.8M | -$46.4M | $160.4M |
| 2022 | $49.0M | -$66.8M | $21.3M | -$61.2M | $89.9M |
| 2021 | $22.6M | -$48.7M | $4.5M | -$46.6M | $138.2M |
| 2020 | $14.7M | $27.6M | $1.7M | -$37.7M | -$430.6M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 5.56 (safe)
- Working capital / assets 0.838
- Retained earnings / assets -2.12
- EBIT / assets -0.155
- Equity / liabilities 7.63
Source: SEC EDGAR filings · CIK 0001111485 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.